CompletedPhase 2NCT01981837

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alnylam Pharmaceuticals
Principal Investigator
Jared Gollob, MD
Alnylam Pharmaceuticals
Intervention
ALN-TTRSC (revusiran) for subcutaneous administration(drug)
Enrollment
26 enrolled
Eligibility
18-80 years · All sexes
Timeline
20132015

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01981837 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials